Engeli B, Lachenmeier D, Diel P, Guth S, Villar Fernandez M, Roth A
Nutrients. 2025; 17(3).
PMID: 39940347
PMC: 11820564.
DOI: 10.3390/nu17030489.
Froude A, Pangborn N, Britz-McKibbin P, MacKillop J, Balodis I
Cannabis. 2025; 7(3):134-166.
PMID: 39781553
PMC: 11705039.
DOI: 10.26828/cannabis/2024/000271.
Marsigliano K, Green K, DiGangi B
Front Vet Sci. 2024; 11:1448123.
PMID: 39720406
PMC: 11667118.
DOI: 10.3389/fvets.2024.1448123.
Chhabra M, Lewis E, Balshaw R, Stewart B, Zaslawski Z, Lowthian T
PLoS One. 2024; 19(9):e0290185.
PMID: 39302982
PMC: 11414974.
DOI: 10.1371/journal.pone.0290185.
Bedillion M, Claus E, Wemm S, Fox H, Ansell E
Alcohol Clin Exp Res (Hoboken). 2024; 48(6):988-999.
PMID: 38641546
PMC: 11238947.
DOI: 10.1111/acer.15322.
Cannabis and Anxiety: A Critical Review.
Beletsky A, Liu C, Lochte B, Samuel N, Grant I
Med Cannabis Cannabinoids. 2024; 7(1):19-30.
PMID: 38406383
PMC: 10890807.
DOI: 10.1159/000534855.
Δ9-Tetrahydrocannabinol does not upregulate an aversive dopamine receptor mechanism in adolescent brain unlike in adults.
Di Raddo M, Milenkovic M, Sivasubramanian M, Hasbi A, Bergman J, Withey S
Curr Res Neurobiol. 2023; 5:100107.
PMID: 38020805
PMC: 10663137.
DOI: 10.1016/j.crneur.2023.100107.
Exploring the therapeutic potential of natural compounds modulating the endocannabinoid system in various diseases and disorders: review.
Wilson G, Yang L, Su X, Ding S, Li L, Yang Y
Pharmacol Rep. 2023; 75(6):1410-1444.
PMID: 37906390
DOI: 10.1007/s43440-023-00544-7.
Effects of sub-chronic nabiximols on biological markers of individuals undergoing a clinical trial for the treatment of cannabis use disorder.
Wang R, Trigo J, Le Foll B
Am J Transl Res. 2023; 15(8):5228-5238.
PMID: 37692969
PMC: 10492088.
Clinical outcome data of anxiety patients treated with cannabis-based medicinal products in the United Kingdom: a cohort study from the UK Medical Cannabis Registry.
Rifkin-Zybutz R, Erridge S, Holvey C, Coomber R, Gaffney J, Lawn W
Psychopharmacology (Berl). 2023; 240(8):1735-1745.
PMID: 37314478
PMC: 10349732.
DOI: 10.1007/s00213-023-06399-3.
The therapeutic potential of purified cannabidiol.
OSullivan S, Skov Jensen S, Nykjaer Nikolajsen G, Ziegler Bruun H, Bhuller R, Hoeng J
J Cannabis Res. 2023; 5(1):21.
PMID: 37312194
PMC: 10262148.
DOI: 10.1186/s42238-023-00186-9.
Medical cannabinoids for painful symptoms in patients with severe dementia: a randomized, double-blind cross-over placebo-controlled trial protocol.
Bianchi F, Pautex S, Wampfler J, Curtin F, Daali Y, Desmeules J
Front Pain Res (Lausanne). 2023; 4:1108832.
PMID: 37293434
PMC: 10244760.
DOI: 10.3389/fpain.2023.1108832.
Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review.
Hasbi A, Madras B, George S
Brain Sci. 2023; 13(2).
PMID: 36831868
PMC: 9953886.
DOI: 10.3390/brainsci13020325.
Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
Zamarripa C, Spindle T, Surujunarain R, Weerts E, Bansal S, Unadkat J
JAMA Netw Open. 2023; 6(2):e2254752.
PMID: 36780161
PMC: 9926328.
DOI: 10.1001/jamanetworkopen.2022.54752.
THC and CBD: Similarities and differences between siblings.
Stella N
Neuron. 2023; 111(3):302-327.
PMID: 36638804
PMC: 9898277.
DOI: 10.1016/j.neuron.2022.12.022.
The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence.
Arnold J, McCartney D, Suraev A, McGregor I
Clin Transl Sci. 2022; 16(1):10-30.
PMID: 36259271
PMC: 9841308.
DOI: 10.1111/cts.13425.
Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis.
Hutten N, Arkell T, Vinckenbosch F, Schepers J, Kevin R, Theunissen E
Psychopharmacology (Berl). 2022; 239(11):3731-3741.
PMID: 36227352
PMC: 9584997.
DOI: 10.1007/s00213-022-06248-9.
Cannabidiol as a personalized treatment for anxiety: clinical cases in Mexico.
Ortiz Rios F, Davila Ruiz I, Sacal Dumani E
Drugs Context. 2022; 11.
PMID: 36188636
PMC: 9491383.
DOI: 10.7573/dic.2022-3-2.
Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions.
Henson J, Vitetta L, Hall S
Inflammopharmacology. 2022; 30(4):1167-1178.
PMID: 35796920
PMC: 9294022.
DOI: 10.1007/s10787-022-01020-z.
Enhancing Endocannabinoid Control of Stress with Cannabidiol.
Henson J, Vitetta L, Quezada M, Hall S
J Clin Med. 2021; 10(24).
PMID: 34945148
PMC: 8704602.
DOI: 10.3390/jcm10245852.
